Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: A pilot Phase II clinical trial and pharmacokinetic profile

Cancer

Volumn 85, Issue 11, 1999, Pages 2375-2384

  Nakano, Takashi ^a   Chahinian, A Philippe ^b   Shinjo, Miho ^a   Togawa, Naoki ^a   Tonomura, Atsushi ^a   Miyake, Mitsutomi ^a   Ninomiya, Koji ^a   Yamamoto, Tetsuya ^a   Higashino, Kazuya ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Cisplatin; Irinotecan; Mesothelioma; Phamacokinetics; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ATROPINE; CISPLATIN; FLUOROURACIL; GRANISETRON; IRINOTECAN; KAMPO; LOPERAMIDE; ONDANSETRON; PACLITAXEL; TIMIPERONE; TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INTRAPLEURAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; OCCUPATIONAL EXPOSURE; PHASE 2 CLINICAL TRIAL; PLEURA FLUID; PLEURA METASTASIS; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MESOTHELIOMA; MIDDLE AGED; PILOT PROJECTS; PLEURAL DISEASES;

EID: 0033153309     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.0.CO;2-E     Document Type: Article

References (59)

1. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345:535-9.
2. de Klerk NH, Armstrong BK. The epidemiology of asbestos and mesothelioma. Henderson DW, Shelkin KB, Langlois SLP, Whitaker D, editors. Malignant mesothelioma. New York: Hemisphere, Inc., 1992:223-43.
3. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer 1993;72:394-404.
4. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995;108:1122-8.
5. Rush VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991;102:1-9.
6. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995;107:332S-44S.
7. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996;14:1007-17.
8. Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R. Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985;69: 711-2.
9. Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 1988;6:223-6.
10. Zidar BL, Pugh RP, Schiffer LM, Raju RN, Vaidya KA, Bloom RL, et al. Treatment of six of mesothelioma with doxorubicin and cisplatin. Cancer 1983;52:1788-91.
11. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant mesothelioma. Cancer 1991;67:2984-7.
12. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993;11: 1559-65.
13. Kraruf-Hansen A. Phase II trials of malignant mesothelioma: a commentary and update. Lung Cancer 1994;11: 305-8.
14. Vogelzang NJ. Malignant mesothelioma: diagnosis and management strategies for 1992. Semin Oncol 1992;19(Suppl 11):64-71.
15. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-7.
16. Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boue A, Houghton JA. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethlyaminomethly-10-hydroxycamptothecin. Cancer Res 1993;53:2823-9.
17. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988;21: 71-4.
18. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camtothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992;10: 16-20.
19. Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 1991;18:1013-9.
20. Masuda N, Fukuoka M, Kusunoki Y, Takifuji N, Kudoh S, Negoro S, et al. CPT-11, a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-9.
21. Wiseman LR, Markham A. Irinotecan, a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996;52:606-23.
22. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604-10.
23. Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 1994;85:966-71.
24. Kudoh S, Takada M, Masuda N, Nakagawa K, Itoh K, Kusunoki Y, et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 1993;84:203-7.
25. Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA III, Degen D, von Hoff DD. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 1994; 5:202-6.
26. Vogelzang NJ, Herndon JE, Cirrincione C, Harmon DC, Antman KH, Corson JM, et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer 1997;79:2237-42.
27. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990;50:1715-20.
28. Sasaki Y, Mizuno S, Fujii H, Ohtsu T, Wakita H, Igarashi T, et al. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38. Jpn J Cancer Res 1995;86:117-23.
29. Ghosh BK. A comparison of some approximate confidence intervals for binomial parameter. J Am Stat Assoc 1979;74: 894-900.
30. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187-91.
31. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 1991;14:341-9.
32. Fukuoka M, Masuda N. Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 1994;34:S105-11.
33. Masuda N, Fukuoka M, Takada M, Negoro S, Matsui K, Kudoh S, et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992;10: 1775-80.
34. Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, et al. Phase 1 and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 1994;12:1833-41.
35. van Meerbeeck J, Debruyne C, van Zandwijk N, Postmus PE, Pennucci MC, van Breukelen F, et al. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996; 74:961-3.
36. Vogelzang NJ, Herndon U, Clamon GH, Mauer AM, Cooper MR, Green MR. Paclitaxel (Taxol) for malignant mesothelioma (MM): a phase II study of the Cancer and Leukemia Group B(CALGB 9234) [abstract]. Proc Am Soc Clin Oncol 1994;13:405.
37. Caliandro R, Boutin C, Perol M, Monnet I, Dabouis G, Guerin JC, et al. Phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in advanced pleural malignant mesothelioma [abstract]. Fourth International Mesothelioma Interest Group Meeting, 1997:49.
38. Vogelzang NJ, Weissman LB, Herndon JE, Karen H, Antman KH, Cooper MR, et al. Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B phase II study. J Clin Oncol 1994;12:1436-42.
39. Maksymiuk AW, Jung S, Marschke RF, Nair S, Jett JR. Phase II trial of topotecan in pleural mesothelioma: a North Central Cancer Treatment Group(NCCTG) trial [abstract]. Proc Am Soc Clin Oncol 1995;14:285.
40. O'Reilly S, Rowinsky EK. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit Rev Oncol Hematol 1996;24:47-70.
41. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113:723-31.
42. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase 1 and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-21.
43. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959-67.
44. Rothenberg ML, Kuhn JG, Burris HA III, Nelson J, Eckardt JR, Tristan-Marales M, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993;11:2194-204.
45. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991;83:1164-8.
46. de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994;54: 4347-54.
47. Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995;6:133-40.
48. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15:1502-10.
49. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, et al. Population pharmacokinetics and pharmacodynamics of irinotecan(CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995;6:141-51.
50. Burris HA III, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992;84:1816-20.
51. Houghton PJ, Cheshire PJ, Hallman JD II, Lutz L, Friedman HS, Danks MK, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
52. Sasaki Y, Ohtsu A, Shimada Y, Ono K, Saijo N. Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994;86: 1096-8.
53. Armand JP, Terret C, Couteau C, Rixe O. CPT-11. the European experience. Ann NY Acad Sci 1996;803:282-91.
54. Society of Japanese Pharmacopoeia. Irinothecan hydrochloride, summary basis of approval no. 1 (revised edition). Pharmaceuticals and Cosmetics Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, editor. Tokyo: Yakujinippo, Inc., 1996:105.
55. Grem JL, Ellenberg SS, King SA, Shoemaker DD. Correlates of severe or life-threatening toxic effects from trimetrexate. J Natl Cancer Inst 1988;80:1313-8.
56. Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H, et al. Malignant mesothelioma of the pleura. Klin Wochenschr 1988;66;607-13.
57. Pisani RJ. Malignant mesothelioma of the pleura. Mayo Clin Proc 1988;63:1234-44.
58. van Meerbeeck JP. Prognostic factors in malignant mesothelioma: where do we go from here? Eur Respir J 1994;6:1029-31.
59. Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH, et al. Node status has prognostic significance in the multimodality therapy of diffuse malignant mesothelioma. J Clin Oncol 1993;11:1172-8.